Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor …

BERKELEY, Calif.–(BUSINESS WIRE)–Jun 24, 2021–. Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its …

Continue

Do you trust this headline?

Based on recent headline ratings, 66% of this readership currently trusts the local media, which has an average score of 85% regionally and is currently trending negative.

66%

Media Trust Score66%

Read All

In

News